<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-251 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-251</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-251</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-12.html">extraction-schema-12</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, clinical findings, and evidence explaining the association between thymomas and autoimmunity.</div>
                <p><strong>Paper ID:</strong> paper-11990e0087aba7222efbe382c1a75f3639151767</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/11990e0087aba7222efbe382c1a75f3639151767" target="_blank">Concurrent de novo Thymoma-associated Paraneoplastic Type 1 Autoimmune Hepatitis and Pure Red Cell Aplasia after Thymectomy: A Case Report and Literature Review</a></p>
                <p><strong>Paper Venue:</strong> Internal medicine</p>
                <p><strong>Paper TL;DR:</strong> The case of a 50-year-old lady with concurrent de novo type 1 autoimmune hepatitis (AIH) and pure red cell aplasia (PRCA), 1 month after undergoing a successful total thymectomy for combined squamous cell carcinoma and thymoma, is presented.</p>
                <p><strong>Paper Abstract:</strong> The precise manipulation of immune tolerance is the holy grail of immunotherapies for both autoimmunity and cancer immunity. Thymomas are well known to be associated with autoimmune diseases. The exact mechanism by which autoreactivity is induced after thymectomy remains to be elucidated. We herein present the case of a 50-year-old lady with concurrent de novo type 1 autoimmune hepatitis (AIH) and pure red cell aplasia (PRCA), 1 month after undergoing a successful total thymectomy for combined squamous cell carcinoma and thymoma (Masaoka stage II). Corticosteroids yielded short-term effects for both AIH and PRCA. Literature on thymoma-associated AIH, an extremely rare immune-related comorbidity, was also reviewed.</p>
                <p><strong>Cost:</strong> 0.014</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e251.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e251.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, clinical findings, and evidence explaining the association between thymomas and autoimmunity.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Paraneoplastic autoimmunity (thymoma)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Paraneoplastic autoimmune diseases associated with thymoma</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Clinical association between thymic epithelial tumors (thymomas/thymic carcinoma) and a spectrum of autoimmune/paraneoplastic diseases, most prominently myasthenia gravis but including PRCA, SLE, autoimmune thyroid disease, polymyositis, bullous pemphigoid, hypogammaglobulinemia and others.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Thymoma associated with autoimmune diseases: 85 cases and literature review.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmune_disease_name</strong></td>
                            <td>Myasthenia gravis (MG), pure red cell aplasia (PRCA), systemic lupus erythematosus (SLE), autoimmune thyroid diseases, polymyositis, bullous pemphigoid, hypogammaglobulinemia, Good's syndrome, autoimmune hepatitis (AIH)</td>
                        </tr>
                        <tr>
                            <td><strong>prevalence_in_thymoma_patients</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Paraneoplastic induction of organ-specific autoimmunity via thymic epithelial tumor disruption of normal thymic education (positive/negative selection), aberrant antigen presentation, and generation/escape of autoreactive T cells.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>Epidemiologic and case-series observations of multiple autoimmune diseases co-occurring with thymomas (literature review identifying many cases); this paper's case and table of 13 thymoma-associated AIH cases; earlier reviews documenting high frequency of MG and other autoimmune comorbidities.</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>patient_demographics</strong></td>
                            <td>From the paper's AIH-with-thymoma series (n=13): median age 35 years (range 25-77), female preponderance 61.5% (8/13); no clear ethnic predilection reported.</td>
                        </tr>
                        <tr>
                            <td><strong>interventions_modulating_autoimmunity</strong></td>
                            <td>Thymectomy (variable effects: frequently remits MG but can precede de novo or relapsing paraneoplastic autoimmunity such as PRCA and AIH); immunosuppression (corticosteroids, cyclosporine A), plasma exchange, chemotherapy reported in some case reports.</td>
                        </tr>
                        <tr>
                            <td><strong>key_findings</strong></td>
                            <td>Thymomas are associated with a heterogeneous set of autoimmune diseases; most thymoma-associated AIH cases present before thymectomy, but de novo post-thymectomy onset can occur; many patients with thymoma-associated AIH have at least one other autoimmune disease (84.6% in the collected cases).</td>
                        </tr>
                        <tr>
                            <td><strong>limitations</strong></td>
                            <td>Data derive primarily from case reports and small series; no population-level prevalence estimates provided; heterogeneity in case ascertainment and reporting.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Concurrent de novo Thymoma-associated Paraneoplastic Type 1 Autoimmune Hepatitis and Pure Red Cell Aplasia after Thymectomy: A Case Report and Literature Review', 'publication_date_yy_mm': '2022-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e251.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e251.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, clinical findings, and evidence explaining the association between thymomas and autoimmunity.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Immature T cell theory</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Immature T cell escape (defective negative selection) theory</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Hypothesis that thymomas contain or allow the escape of immature T cells that have not undergone proper positive/negative selection, permitting autoreactive T cells to enter the periphery and cause autoimmunity.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Thymoma and autoimmunity.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmune_disease_name</strong></td>
                            <td>Various paraneoplastic autoimmune diseases (e.g., MG, PRCA, AIH) linked to thymoma</td>
                        </tr>
                        <tr>
                            <td><strong>prevalence_in_thymoma_patients</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Thymic epithelial neoplasia perturbs normal intrathymic selection, allowing autoreactive T cells (insufficiently negatively selected) to emigrate and mediate organ-specific autoimmunity.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>Conceptual and pathological observations that thymomas contain immature T cells and disrupted thymic architecture; cited literature on thymic function and thymoma biology supporting dysfunctional central tolerance.</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_evidence</strong></td>
                            <td>Inconsistent effects of thymectomy on autoimmunity (some autoimmune diseases remit after thymectomy, others develop or relapse), indicating this mechanism alone may not explain all post-thymectomy autoimmunity.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_demographics</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>interventions_modulating_autoimmunity</strong></td>
                            <td>Thymectomy may remove a source of abnormal T-cell development but can also be followed by de novo autoimmune disease, suggesting complex effects on tolerance.</td>
                        </tr>
                        <tr>
                            <td><strong>key_findings</strong></td>
                            <td>The immature T cell escape idea remains a leading hypothesis but cannot fully explain cases of de novo autoimmunity after thymectomy described in the paper.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations</strong></td>
                            <td>Hypothesis based on inferential pathology and prior literature; direct mechanistic human data are limited in the reviewed cases.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Concurrent de novo Thymoma-associated Paraneoplastic Type 1 Autoimmune Hepatitis and Pure Red Cell Aplasia after Thymectomy: A Case Report and Literature Review', 'publication_date_yy_mm': '2022-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e251.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e251.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, clinical findings, and evidence explaining the association between thymomas and autoimmunity.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Neoplastic-genetic theory</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neoplastic-genetic theory (increased autoreactivity due to tumor-driven changes)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Hypothesis that thymic epithelial tumors intrinsically alter the thymic microenvironment or express aberrant antigens/genetics that promote autoreactive T-cell proliferation and autoimmunity.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Thymoma and autoimmunity.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmune_disease_name</strong></td>
                            <td>Paraneoplastic autoimmune syndromes including MG, PRCA, AIH</td>
                        </tr>
                        <tr>
                            <td><strong>prevalence_in_thymoma_patients</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Genetic/neoplastic changes within thymic epithelial cells modify antigen presentation or provide proliferative signals that enhance autoreactive T-cell expansion and function.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>Theoretical framework cited in reviews; observations of thymomas co-occurring with diverse autoimmune syndromes and presence of immature/aberrant lymphoid populations within tumors.</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_evidence</strong></td>
                            <td>Does not explain delayed de novo autoimmunity after thymectomy in all cases; limited direct molecular/genetic evidence linking specific tumor alterations to specific autoantigens in humans.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_demographics</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>interventions_modulating_autoimmunity</strong></td>
                            <td>Tumor-directed therapies (thymectomy, chemotherapy) have variable effects on autoimmune manifestations, consistent with complex tumor-host interactions.</td>
                        </tr>
                        <tr>
                            <td><strong>key_findings</strong></td>
                            <td>Neoplastic-genetic mechanisms are plausible contributors but remain incompletely defined by human data presented in the paper.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations</strong></td>
                            <td>Largely theoretical; human molecular evidence is sparse in the case series reviewed.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Concurrent de novo Thymoma-associated Paraneoplastic Type 1 Autoimmune Hepatitis and Pure Red Cell Aplasia after Thymectomy: A Case Report and Literature Review', 'publication_date_yy_mm': '2022-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e251.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e251.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, clinical findings, and evidence explaining the association between thymomas and autoimmunity.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>AIRE deficiency link</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>AIRE deficiency / APS-1-associated autoimmunity</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>AIRE gene mutations (autoimmune regulator) cause failure to express tissue-restricted antigens in medullary thymic epithelial cells, leading to multiorgan autoimmunity (APS-1); the thymic medulla's role in central tolerance implicates AIRE-related pathways in thymoma-associated tolerance defects.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>RANK signals from CD4+3 inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmune_disease_name</strong></td>
                            <td>Autoimmune polyendocrine syndrome type 1 (APS-1) and rare cases of AIH linked to AIRE mutations</td>
                        </tr>
                        <tr>
                            <td><strong>prevalence_in_thymoma_patients</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Loss or dysfunction of AIRE-expressing medullary thymic epithelial cells reduces negative selection of autoreactive T cells and impairs central tolerance, permitting multi-organ autoimmunity.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>Reference to genetic syndrome (AIRE mutation) known to cause AIH and other autoimmune diseases; citation of studies on AIRE expression requiring RANK signaling in thymic medulla.</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_evidence</strong></td>
                            <td>AIRE mutation–driven autoimmunity is rare and genetic AIRE defects are not reported in typical thymoma patients in this paper; thus direct applicability to thymoma cases is uncertain.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_demographics</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>interventions_modulating_autoimmunity</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>key_findings</strong></td>
                            <td>AIRE-related loss of central tolerance is a well-established mechanism for some autoimmune diseases and is discussed as a model illuminating how thymic dysfunction can lead to autoimmunity, but it does not directly explain most thymoma-associated cases.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations</strong></td>
                            <td>APS-1 is genetically defined and distinct from thymoma; the paper notes this as a 'rare exception' and does not present direct genetic data linking AIRE defects to thymoma cases.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Concurrent de novo Thymoma-associated Paraneoplastic Type 1 Autoimmune Hepatitis and Pure Red Cell Aplasia after Thymectomy: A Case Report and Literature Review', 'publication_date_yy_mm': '2022-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e251.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e251.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, clinical findings, and evidence explaining the association between thymomas and autoimmunity.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CD8+ cytotoxic T-cell–mediated damage</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>CD8+ cytotoxic (perforin+) T-cell–mediated tissue injury (liver and bone marrow)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Evidence that cytotoxic CD8+ T cells, especially perforin+ effector-memory and tissue-resident CD8+CD103+ cells, mediate destruction of target tissues (bone marrow in PRCA and liver in AIH) in thymoma-associated autoimmunity.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Expansion of CD8+/perforin+ effector memory T cells in the bone marrow of patients with thymoma-associated pure red cell aplasia.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmune_disease_name</strong></td>
                            <td>Pure red cell aplasia (PRCA) and autoimmune hepatitis (AIH)</td>
                        </tr>
                        <tr>
                            <td><strong>prevalence_in_thymoma_patients</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Autoreactive cytotoxic CD8+ T cells (perforin+) infiltrate target organs (bone marrow or liver) and mediate cell death, causing PRCA and AIH respectively; tissue-resident memory CD8+CD103+ cells may be involved in liver injury.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>This paper's liver biopsy demonstrated predominant CD8+ T-cell infiltration (immunohistochemistry); literature reports expansion of CD8+/perforin+ effector memory T cells in bone marrow of thymoma-associated PRCA patients (Nitta et al.); pediatric AIH studies show intrahepatic CD8+CD103+perforin+ populations in acute presentations.</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_evidence</strong></td>
                            <td>A referenced cohort study reported decreased peripheral CD8+ frequencies and an elevated CD4/CD8 ratio after thymectomy in patients with hypertransaminasemia and thymoma, which complicates a simple model of CD8-mediated disease driven solely by increased peripheral CD8 counts.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_demographics</strong></td>
                            <td>In this case: 50-year-old Japanese woman with de novo AIH and PRCA 1 month after thymectomy; liver histology showed CD8+ predominance.</td>
                        </tr>
                        <tr>
                            <td><strong>interventions_modulating_autoimmunity</strong></td>
                            <td>Corticosteroids led to rapid improvement in liver enzymes and a later rise in reticulocytes; cyclosporine A is suggested as a potential therapy for PRCA (and as alternative in AIH).</td>
                        </tr>
                        <tr>
                            <td><strong>key_findings</strong></td>
                            <td>The paper links CD8+ cytotoxic T-cell infiltration to both liver injury (predominant CD8+ cells in biopsy) and bone marrow failure (literature), supporting a shared CD8-mediated pathogenic mechanism in thymoma-associated PRCA and AIH.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations</strong></td>
                            <td>Direct demonstration of antigen specificity or clonality of CD8+ cells in this patient was not performed; mechanistic causality is inferred from histology and prior studies rather than proven in this case.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Concurrent de novo Thymoma-associated Paraneoplastic Type 1 Autoimmune Hepatitis and Pure Red Cell Aplasia after Thymectomy: A Case Report and Literature Review', 'publication_date_yy_mm': '2022-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e251.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e251.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, clinical findings, and evidence explaining the association between thymomas and autoimmunity.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Treg deficiency post-thymectomy</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Regulatory T cell (Treg) deficiency and loss of peripheral tolerance after thymectomy</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Loss or reduction of naturally arising CD4+CD25+FOXP3+ regulatory T cells after thymectomy (or impaired development) can disrupt peripheral immune regulation, permitting autoreactive T-cell activation and de novo autoimmunity.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory T cells and PD-1-mediated signaling.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmune_disease_name</strong></td>
                            <td>De novo autoimmune diseases after thymectomy including AIH, PRCA and others</td>
                        </tr>
                        <tr>
                            <td><strong>prevalence_in_thymoma_patients</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Thymectomy removes a source of Treg export or impairs the thymic environment needed for Treg development, reducing maintenance of peripheral tolerance and enabling autoreactive cells to cause organ-specific autoimmunity; synergistic loss with checkpoint pathways (e.g., PD-1) exacerbates disease in animal models.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>Murine model cited: neonatal thymectomy combined with PD-1 ablation caused fatal hepatitis resembling human AIH and was associated with severe reduction of Tregs; long-term immunologic studies in MG patients show persistent immunologic effects after thymectomy.</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>patient_demographics</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>interventions_modulating_autoimmunity</strong></td>
                            <td>Thymectomy itself is implicated as a precipitant of de novo autoimmunity via Treg reduction; immunosuppressive therapies (steroids, CsA) can restore control clinically.</td>
                        </tr>
                        <tr>
                            <td><strong>key_findings</strong></td>
                            <td>Authors propose that thymectomy can disable maintenance of immune tolerance by dysregulating Treg development, which may explain de novo autoimmunity after thymectomy; supported by animal model data.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations</strong></td>
                            <td>Human direct measurements of Treg number/function before and after thymectomy in these cases are not presented; murine model findings may not fully translate to adult human thymectomy scenarios.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Concurrent de novo Thymoma-associated Paraneoplastic Type 1 Autoimmune Hepatitis and Pure Red Cell Aplasia after Thymectomy: A Case Report and Literature Review', 'publication_date_yy_mm': '2022-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e251.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e251.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, clinical findings, and evidence explaining the association between thymomas and autoimmunity.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Autoantibodies (ASMA/LKM/CYP1A2)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Serologic autoantibodies observed in thymoma-associated AIH (anti-smooth muscle (ASMA), anti-LKM3, anti-CYP1A2)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Detection of autoantibodies (e.g., ASMA/F-actin, anti-LKM3, cytochrome P450 1A2) in some thymoma-associated AIH cases suggests humoral autoimmune responses potentially linked to thymic antigen presentation abnormalities.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Smooth muscle autoantibodies and autoantigens.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmune_disease_name</strong></td>
                            <td>Autoimmune hepatitis (type 1 and type 2), APS-1–associated hepatitis</td>
                        </tr>
                        <tr>
                            <td><strong>prevalence_in_thymoma_patients</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Aberrant thymic expression or presentation of tissue-specific antigens may induce autoantibody formation; thymic medulla shows reactivity to smooth muscle autoantibodies, and specific hepatic autoantigens (UGT1A for LKM3, CYP1A2) have been reported in related contexts.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>This patient was ASMA-positive (40x); literature reports ASMA positivity in other thymoma-associated AIH cases; prior studies identified thymic medulla reactivity to smooth muscle autoantibodies and reported hepatic autoantigens like LKM-3 (UGT1A) and CYP1A2 in related syndromes.</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_evidence</strong></td>
                            <td>The molecular/immunological links between these autoantibodies and direct tissue injury remain unclear; autoantibodies are inconsistently present across cases and their pathogenic role is not established.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_demographics</strong></td>
                            <td>In the reported case: ASMA 40-fold positive, IgG 1,220 mg/dL and compatible IAIHG score for type 1 AIH.</td>
                        </tr>
                        <tr>
                            <td><strong>interventions_modulating_autoimmunity</strong></td>
                            <td>Immunosuppression (corticosteroids) reduced liver inflammation despite autoantibody presence.</td>
                        </tr>
                        <tr>
                            <td><strong>key_findings</strong></td>
                            <td>Autoantibody detection (ASMA in this patient and others) supports a humoral autoimmune component in some thymoma-associated AIH cases, but the connection to thymic antigen presentation requires further study.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations</strong></td>
                            <td>Autoantibodies are neither universally present nor proven to be directly pathogenic in these thymoma-associated cases; mechanistic links are speculative.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Concurrent de novo Thymoma-associated Paraneoplastic Type 1 Autoimmune Hepatitis and Pure Red Cell Aplasia after Thymectomy: A Case Report and Literature Review', 'publication_date_yy_mm': '2022-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Thymoma and autoimmunity. <em>(Rating: 2)</em></li>
                <li>Thymus and autoimmunity. <em>(Rating: 2)</em></li>
                <li>Expansion of CD8+/perforin+ effector memory T cells in the bone marrow of patients with thymoma-associated pure red cell aplasia. <em>(Rating: 2)</em></li>
                <li>Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory T cells and PD-1-mediated signaling. <em>(Rating: 2)</em></li>
                <li>Indeterminate pediatric acute liver failure is uniquely characterized by a CD103+CD8+ T-cell infiltrate. <em>(Rating: 2)</em></li>
                <li>Clinical and genetic characteristics of thymoma patients with autoimmune hepatitis and myocarditis. <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>